On-demand virtual event
Biological & Medicinal Chemistry
DNA-encoded library (DEL) technology has proven to be a powerful tool for drug discovery. There are now several DEL-derived candidates in clinical stage. DEL enables researchers to explore vast chemical space with millions to billions of compounds with low cost, limited time and minimal effort.
Scientists in both industry and academics are both trying to further expand the utility of DEL. WuXi AppTec has been practicing DELopen collaborations with many university researchers with free DEL kits. This has significantly spread the DEL compounds into many drug discovery labs and accelerated the research process. WuXi AppTec has also been providing DEL kit services for our industrial partners to help them implement DEL as one of the benchtop drug discovery tools.
However, to fully promote DEL screening ideas to the next level, it would not be sufficient to just distribute DEL compounds into the lab. The standardization of the screening procedure is paramount. Given that a DEL screen needs several rounds of experiments to enrich the compounds, it is vital to lower the contamination and human error in operation to a negligible level for a qualified screen.
WuXi AppTec has profound DEL screening experience on a wide spectrum of proteins. With the combination of the automatic system, WuXi AppTec has released the first automatic DEL screening device - DELman. With DELman and other self-service data analysis tools, researchers can easily wield DEL screens in appointed scenarios and obtain stable and reliable screening outcomes.
Wenji Su, PhD
Executive Director, Head of Early Discovery Platform, WuXi Biology
Weiren Cui, PhD
Director, Head of Hit Finding and Informatics Department, Early Discovery Platform, WuXi Biology
Chang Liu, PhD
Associate Director, Early Discovery Platform, WuXi Biology
Keep learning. Excel in your career.
Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.